Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Next Previous
Trial Profile

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luveltamab tazevibulin (Primary) ; Bevacizumab
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms REFRaME-L1
  • Sponsors Sutro Biopharma

Most Recent Events

  • 19 Aug 2024 Status changed from planning to not yet recruiting.
  • 14 May 2024 According to a Sutro Biopharma media release, expected to begin enrolling patients in the second half of 2024, Patient expansion phase well underway ; enrollment is expected to complete in the first half of 2024, initial data is expected in the first half of 2025.
  • 14 May 2024 According to a Sutro Biopharma media release, Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top